Milestone Pharmaceuticals Net Income Over Time
| MIST Stock | USD 1.76 0.04 2.33% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Milestone Pharmaceuticals Performance and Milestone Pharmaceuticals Correlation. Milestone | Build AI portfolio with Milestone Stock |
Is there potential for Pharmaceuticals market expansion? Will Milestone introduce new products? Factors like these will boost the valuation of Milestone Pharmaceuticals. Expected growth trajectory for Milestone significantly influences the price investors are willing to assign. Understanding fair value requires weighing current performance against future potential. All the valuation information about Milestone Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Investors evaluate Milestone Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Milestone Pharmaceuticals' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. External factors like market trends, sector rotation, and investor psychology can cause Milestone Pharmaceuticals' market price to deviate significantly from intrinsic value.
Understanding that Milestone Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Milestone Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Milestone Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Net Income Analysis
Compare Milestone Pharmaceuticals and related stocks such as Rani Therapeutics, Molecular Partners, and Applied Therapeutics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RANI | (26.6 M) | (26.6 M) | (26.6 M) | (26.6 M) | (26.6 M) | (26.6 M) | (26.6 M) | (26.6 M) | (26.6 M) | (26.6 M) | (16.7 M) | (8.3 M) | (30.6 M) | (34 M) | (30 M) | (27 M) | (28.4 M) |
| MOLN | 7.1 M | 7.1 M | 7.1 M | 7.1 M | (2.3 M) | (148.8 K) | (18.6 M) | (25.4 M) | (37 M) | (36.3 M) | (62.8 M) | (63.8 M) | 117.9 M | (62 M) | (54 M) | (48.6 M) | (46.2 M) |
| APLT | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (16.5 M) | (45.4 M) | (93 M) | (104.6 M) | (82.5 M) | (119.8 M) | (105.6 M) | (95.1 M) | (99.8 M) |
| CRDF | (5.4 M) | (2.2 M) | (11.6 M) | (11.8 M) | (14.3 M) | (27.5 M) | (39.2 M) | (24.9 M) | (16.5 M) | (16.4 M) | (19.3 M) | (28.3 M) | (38.7 M) | (41.4 M) | (45.4 M) | (40.9 M) | (38.8 M) |
| ELTX | 307.3 K | 307.3 K | 307.3 K | 632.2 K | (20 M) | (20 M) | (20 M) | (20 M) | (20 M) | (40.7 M) | (80.1 M) | (26.4 M) | (28.2 M) | (35.2 M) | (51.9 M) | (46.7 M) | (49 M) |
| IPHA | (6.1 M) | (7 M) | (3.2 M) | (2.9 M) | (19.6 M) | (6.7 M) | 12.6 M | (48.4 M) | 3 M | (20.8 M) | (64 M) | (52.8 M) | (58.1 M) | (7.6 M) | (49.5 M) | (44.5 M) | (42.3 M) |
| CRBP | (887) | (887) | (887) | (602.4 K) | (2.5 M) | (8.9 M) | (20 M) | (32.4 M) | (55.7 M) | (71.5 M) | (111.3 M) | (45.6 M) | (55.8 M) | (44.6 M) | (40.2 M) | (36.2 M) | (38 M) |
| SAVA | (4.5 M) | (2.6 M) | (3.4 M) | 31.5 M | (12.4 M) | (14.1 M) | (14.8 M) | (11.9 M) | (6.6 M) | (4.2 M) | (6.3 M) | (31.8 M) | (72.5 M) | (97.2 M) | (24.3 M) | (21.9 M) | (23 M) |
| PEPG | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.9 M) | (27.3 M) | (69.1 M) | (78.6 M) | (90 M) | (81 M) | (76.9 M) |
Milestone Pharmaceuticals and related stocks such as Rani Therapeutics, Molecular Partners, and Applied Therapeutics Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Milestone Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Milestone Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Milestone Pharmaceuticals | MIST |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 1111 Dr Frederik-Philips |
| Exchange | NASDAQ Exchange |
USD 1.76
Additional Tools for Milestone Stock Analysis
When running Milestone Pharmaceuticals' price analysis, check to measure Milestone Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Milestone Pharmaceuticals is operating at the current time. Most of Milestone Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Milestone Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Milestone Pharmaceuticals' price. Additionally, you may evaluate how the addition of Milestone Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.